Younossi, Z. M. et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 44, 1061–1070 (2024).

Article  CAS  PubMed  Google Scholar 

Feng, G. et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 7, 101271 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y. & Zheng, M.-H. Current status and future trends of the global burden of MASLD. Trends Endocrinol. Metab. 35, 697–707 (2024).

Article  CAS  PubMed  Google Scholar 

El-Kassas, M. & Alswat, K. Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: one size fits all this time. J. Hepatol. 80, E66–E68 (2024).

Article  PubMed  Google Scholar 

Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19, 60–78 (2022).

Article  CAS  PubMed  Google Scholar 

Huang, D. Q. et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat. Rev. Dis. Primers 11, 14 (2025).

Article  PubMed  Google Scholar 

Loomba, R. et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol. Hepatol. 9, 1090–1100 (2024).

Article  CAS  PubMed  Google Scholar 

Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497–509 (2024).

Article  PubMed  Google Scholar 

Harrison, S. A. et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J. Hepatol. 82, 7–17 (2025).

Article  CAS  PubMed  Google Scholar 

Vuppalanchi, R. et al. Randomised clinical trial: design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Aliment. Pharmacol. Ther. 60, 17–32 (2024).

Article  CAS  PubMed  Google Scholar 

Armstrong, M. J. et al. Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: post hoc analysis of three randomised controlled trials. Diabetes Obes. Metab. 27, 710–718 (2025).

Article  CAS  PubMed  Google Scholar 

AlAnazi, M. M., Ventura, E. F., Lovegrove, J. A. & Vimaleswaran, K. S. A systematic review of the gene–lifestyle interactions on metabolic disease-related outcomes in Arab populations. Nutrients 16, 2519 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lazarus, J. V. et al. A global research priority agenda to advance public health responses to fatty liver disease. J. Hepatol. 79, 618–634 (2023).

Article  PubMed  Google Scholar